Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma
NCT00219323Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2003
- Primary completion
- Mar 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in asthma, sponsored by Novartis. Started Nov 2003; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00219323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219323.